Objective: To evaluate the risk of myocardial infarction (MI) associated with the use of rivaroxaban.
Methods: We searched PubMed, CINAHL, Cochrane CENTRAL, Scopus, and the Web of Science for randomized controlled trials of rivaroxaban that reported on MI as clinical outcomes. We express the associations as odds ratios and their 95% confidence intervals. A trial sequential analysis was carried out to ensure validity of our findings.
Results: Nine trials were selected (N=53 827), including one study on stroke prophylaxis in atrial fibrillation, two in acute coronary syndrome, four of short-term prophylaxis of deep venous thrombosis, and two for treatment of deep venous thrombosis/pulmonary embolism. Control arms included warfarin, enoxaparin, or placebo administration. Rivaroxaban was associated with a significantly lower risk of MI compared with the agents used in the control group (odds ratio, 0.82; 95% confidence interval, 0.72-0.94; P=0.004). No heterogeneity was noted in the risk (I=0%; P=0.55); trial sequential analysis reinforced the validity of our findings.
Conclusion: Rivaroxaban is associated with a significantly lower risk of MI in a broad spectrum of patients when tested against different controls.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MCA.0000000000000031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Is there a role for nutritional advice during breastfeeding for infant colic relief? A mixed-method study.
Heliyon
January 2025
The Centre for Nutritional Education and Lifestyle Management (CNELM) and Middlesex University, Berkshire, PO Box 3739, Wokingham, RG40 9UA, United Kingdom.
Objective: This study aimed to explore the extent and impact of maternal dietary change for colic relief in a cohort of breastfeeding women.
Method: A mixed-method non-sequential approach was devised, including a web-based survey (n = 66) and three semi-structured interviews.
Results: Most women (70 %) changed their diet while breastfeeding a baby with colic and perceived a positive impact on their babies (63 %).
Background: This study aimed to identify distinct trajectories of serum osmolality within the first 72 h for patients with sepsis-associated encephalopathy (SAE) in the MIMIC-IV and eICU-CRD databases and assess their impact on mortality and adverse clinical outcomes.
Methods: In this retrospective cohort study, patients with SAE from the MIMIC-IV database were included. Group-based trajectory modeling (GBTM) was used to categorize distinct patterns of serum osmolality changes over 72 h in ICU patients.
Jinbei oral liquid for idiopathic pulmonary fibrosis: a randomized placebo-controlled trial.
Sci Rep
January 2025
Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, People's Republic of China.
The traditional Chinese medicine compound preparation known as Jinbei Oral Liquid (JBOL) consists of 12 herbs, including Astragalus membranaceus (Fisch.) Bge, Codonopsis pilosula (Franch.) Nannf, et al.
View Article and Find Full Text PDFBackground And Aims: Pancreatic fluid collections (PFCs), including walled-off necrosis (WON), are significant complications of acute pancreatitis, and their management often involves drainage, although the optimal type of stent for this purpose remains uncertain. This meta-analysis aimed to compare metal versus plastic stents for endoscopic ultrasound (EUS)-guided drainage of PFCs.
Methods: We searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs) comparing metal with plastic stents for drainage of PFCs.
Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study.
Lancet Infect Dis
January 2025
Research and Development, Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA; Division of Gastroenterology, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, WA, USA.
Background: New respiratory syncytial virus (RSV) vaccines have been approved in the USA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older. Information on the real-world effectiveness of these vaccines is needed.
Methods: We used electronic health records in the Veterans Health Administration to emulate a target trial comparing a single dose of a recombinant stabilised prefusion F protein RSV vaccine versus no vaccination among veterans aged 60 years and older.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!